logo
  

L-3 Communications Q2 Results Miss View; Lowers 2015 Earnings Outlook

L-3 Communications Holdings Inc. (LLL) posted second-quarter net income attributable to the company of $120 million or $1.44 per share, down from $137 million or $1.53 per share in the year-ago period.

The latest quarter's results impacted by $0.77 per share for pre-tax charges of $103 million for contract cost growth at Platform Integration division of Aerospace.

Adjusted net income attributable to the company for the latest quarter was $117 million or $1.41 per share, compared to $137 million or $1.53 per share in the comparable quarter last year.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $1.71 per share. Analysts' estimates typically exclude special items.

Consolidated net sales for the quarter were $2.79 billion, down 7% from $3.02 billion in the prior year period. Analysts expected revenues of $2.88 billion for the quarter.

For fiscal 2015, the company now forecasts earnings of $6.55 to $6.85 per share, adjusted earnings of $6.70 to $7.00 per share and net sales in a range of $11.45 billion to $11.65 billion.

Earlier, the company forecast earnings of $7.17 to $7.47 per share, adjusted earnings of $7.35 to $7.65 per share and net sales of $11.45 billion to $11.65 billion.

Analysts project annual earnings of $7.55 per share and revenues of $11.561 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT